00928.HK
King International Investment Limited
HKSE · Healthcare · Medical - Diagnostics & Research · HK
HKD 0.12
−0.83%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 184.0M | 143.2M | 40.8M | 233.7M | 223.9M |
| Cost of Revenue | 162.2M | 117.9M | 28.0M | 195.9M | 211.8M |
| Gross Profit | 38.1M | 25.4M | 12.7M | 37.8M | 12.0M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 45.2M | 16.3M | 25.9M | 20.2M | 44.6M |
| General & Admin Expense | 25.2M | — | 23.2M | 18.8M | 43.3M |
| Selling & Marketing Expense | 2.7M | — | 2.7M | 1.3M | 1.3M |
| Other Expenses | (3.5M) | — | — | — | — |
| Total Operating Expenses | 41.7M | 16.3M | 25.9M | 20.2M | 44.6M |
| Cost and Expenses | 195.7M | 134.2M | 53.9M | 216.0M | 256.4M |
| Operating Income (EBIT) | (11.7M) | 9.1M | (13.2M) | 17.6M | (32.5M) |
| Non-Operating | |||||
| Interest Income | — | — | — | 1.0K | 10.0K |
| Interest Expense | 3.8M | 3.0M | 793.0K | 200.0K | 227.0K |
| Net Interest Income | (3.8M) | (3.0M) | (793.0K) | (199.0K) | (217.0K) |
| Other Non-Op Income/Expense | (26.6M) | (2.2M) | (31.7M) | 6.3M | 1.8M |
| Non-Operating Income (excl Interest) | 12.9M | — | 31.0M | (6.4M) | (2.0M) |
| EBT (Pre-Tax Income) | (38.1M) | 6.8M | (44.9M) | 23.9M | (30.7M) |
| Income Tax Expense | 7.5M | 5.0M | 2.5M | 8.8M | 1.0M |
| Bottom Line | |||||
| Net Income | (45.6M) | 1.8M | (47.5M) | 15.8M | (25.2M) |
| Earnings from Cont. Ops | (45.6M) | 1.8M | (47.5M) | 15.1M | (31.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (45.6M) | 1.8M | (47.5M) | 15.8M | (25.2M) |
| Per Share | |||||
| Basic EPS | (HK$0.02) | HK$0.00 | (HK$0.03) | HK$0.01 | (HK$0.02) |
| Diluted EPS | (HK$0.02) | HK$0.00 | (HK$0.03) | HK$0.01 | (HK$0.02) |
| Revenue Per Share | HK$0.10 | HK$0.08 | HK$0.02 | HK$0.14 | HK$0.15 |
| Shares | |||||
| Basic Shares Outstanding | 1.9B | 1.9B | 1.9B | 1.6B | 1.5B |
| Diluted Shares Outstanding | 1.9B | 1.9B | 1.9B | 1.6B | 1.5B |
| Profitability Metrics | |||||
| EBITDA | (11.1M) | 9.6M | (10.0M) | 27.7M | (26.7M) |
| D&A | 663.0K | 570.0K | 3.2M | 3.6M | 4.0M |
| EBIT | (11.4M) | 9.1M | (13.2M) | 24.1M | (30.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026